Low expression of Mel-18 predicts poor prognosis in patients with breast cancer

B. H. Guo, X. Zhang, H. Z. Zhang, H. L. Lin, Y. Feng, J. Y. Shao, W. L. Huang, H. F. Kung, M. S. Zeng

    Research output: Contribution to journalArticle

    16 Scopus citations


    Background: Our previous study suggested that melanoma nuclear protein 18 (Mel-18) acted as a tumor suppressor in human breast cancer. This study was designed to investigate the clinical and prognostic significance of Mel-18 in breast cancer patients. Patients and methods: Mel-18 was detected by immunohistochemistry in paraffin-embedded tissues from 287 breast cancer patients, of which 287 were from primary cancer sites, 63 from matched adjacent noncancerous sites, and 35 from metastatic lymph nodes. Differences in Mel-18 expression and clinical characteristics were compared by χ2 test. Prognostic outcomes correlated with Mel-18 were examined using Kaplan-Meier analysis and Cox proportional hazards model. Results: The decreased Mel-18 expression is incremental depending upon the magnitude of cancer progression (P < 0.001). Mel-18 was conversely correlated with the pathological classifications (P < 0.001 for T, N, and M classifications, respectively), clinical staging (P < 0.001), and progesterone receptor (P = 0.030). Furthermore, patients with higher level of Mel-18 showed prolonged overall survivals (P < 0.001). The diminished Mel-18 expression may be a risk factor for the patients' survival (P < 0.001). Conclusions: Lower Mel-18 expression is correlated with advanced clinicopathologic classifications and a poor overall survival in breast cancer patients. These findings suggest that Mel-18 may serve as a useful marker in prognostic evaluation for patients.

    Original languageEnglish (US)
    Pages (from-to)2361-2369
    Number of pages9
    JournalAnnals of Oncology
    Issue number12
    StatePublished - Dec 1 2010


    • Bmi-1
    • Breast cancer; Mel-18
    • Polycomb group proteins

    ASJC Scopus subject areas

    • Hematology
    • Oncology

    Fingerprint Dive into the research topics of 'Low expression of Mel-18 predicts poor prognosis in patients with breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Guo, B. H., Zhang, X., Zhang, H. Z., Lin, H. L., Feng, Y., Shao, J. Y., Huang, W. L., Kung, H. F., & Zeng, M. S. (2010). Low expression of Mel-18 predicts poor prognosis in patients with breast cancer. Annals of Oncology, 21(12), 2361-2369. https://doi.org/10.1093/annonc/mdq241